NK3 antagonists represent a novel treatment option for the management of vasomotor symptoms (VMS) associated with menopause. This program will review practical considerations for prescribing this new class of medications, including dosage, side effects, and monitoring requirements. By the end of the session, clinicians will be better equipped with the knowledge and confidence to integrate this treatment into practice when appropriate, using effective clinical decision-making.
This program has received an unrestricted educational grant or in-kind support from Astellas Pharma Canada Inc.
